Eurobloodnet Association
- Address
- 1 Avenue Claude Vellefaux
Sponsor Overview
Specializations
Inherited Anemias
Eurobloodnet Association supports clinical research in inherited anemias, with particular attention to rare forms of red blood cell disorders that affect hemoglobin production and oxygen transport. Its trial portfolio includes studies in rare anemia populations where the main clinical interest is improving erythroid response and reducing transfusion burden.
- Transfusion dependence
- Erythroid response
- Rare inherited anemia
- Hemoglobin improvement
Research activity in this area spans multiple centres across Europe and focuses on patient groups with distinct inherited anemia subtypes, including conditions where reducing the need for transfusion is a central therapeutic goal.
Erythrocyte Membranopathies
The sponsor is active in clinical studies of erythrocyte membranopathies, a group of red cell membrane disorders associated with chronic anemia and altered cell stability. These trials explore treatment options aimed at improving hematologic function and supporting patients with membrane-related anemia syndromes.
- Red cell membrane disorders
- Membranopathy-related anemia
- Hematologic function
- Chronic anemia management
Clinical interest in this domain reflects a focus on rare disorders where maintaining stable red blood cell performance is a key therapeutic concern.
Transfusion Reduction and Blood Disorder Outcomes
Across its studies, Eurobloodnet Association places emphasis on outcomes linked to transfusion reduction, including transfusion independence and measurable decreases in transfusion requirements. These endpoints are especially relevant in patients with thalassemia and other rare anemia syndromes.
- Transfusion independence
- Reduced transfusion burden
- Thalassemia-related anemia
- Clinical hematology outcomes
The sponsor’s research landscape includes patient-centred measures that track changes in anemia severity and the burden of ongoing blood support.
Rare Disease Hematology
As a patient organisation involved in rare disease hematology, the sponsor supports trials addressing unmet needs in uncommon blood disorders across several countries and research sites. Its clinical interests extend to specialised anemia subgroups that require targeted therapeutic approaches.
- Rare hematologic disorders
- Specialised anemia subgroups
- Multicentre research
- Cross-border clinical collaboration
Current studies involve distinct patient populations with inherited red blood cell conditions, reflecting a sustained focus on rare hematologic disease management.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Mitapivat Sulfate Safety and Efficacy in Adult Patients with Erythrocyte Membranopathies |  Denmark The Netherlands | Recruiting |
| LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias |  France Italy | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases2 trials249 other sponsors
Partnered Research Centres
7 centres- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- 80 Avenue Augustin Fliche, 34295 Montpellier
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- 149 Rue De Sevres, 75015 Paris
- Address
- Boulevard de Belfort, 59000 Lille
- Address
- Blegdamsvej 9, 2100 Copenhagen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Eurobloodnet Association.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.